Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Are Selling Jazz Pharmaceuticals Public Limited Company (JAZZ)

While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, increasing oil prices and deteriorating expectations towards the resolution of the trade war with China, many smart money investors kept their cautious approach regarding the current bull run in the second quarter and hedging or reducing many of their long positions. Some fund managers like this one are betting on Dow hitting 40,000 to generate strong returns. However, as we know, big investors usually buy stocks with strong fundamentals that can deliver gains both in bull and bear markets, which is why we believe we can profit from imitating them. In this article, we are going to take a look at the smart money sentiment surrounding Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ).

Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) was in 20 hedge funds’ portfolios at the end of June. JAZZ shareholders have witnessed a decrease in hedge fund interest in recent months. There were 27 hedge funds in our database with JAZZ holdings at the end of the previous quarter. Our calculations also showed that JAZZ isn’t among the 30 most popular stocks among hedge funds (view the video below).
5 Most Popular Stocks Among Hedge Funds
Video: Click the image to watch our video about the top 5 most popular hedge fund stocks.

Hedge funds’ reputation as shrewd investors has been tarnished in the last decade as their hedged returns couldn’t keep up with the unhedged returns of the market indices. Our research has shown that hedge funds’ small-cap stock picks managed to beat the market by double digits annually between 1999 and 2016, but the margin of outperformance has been declining in recent years. Nevertheless, we were still able to identify in advance a select group of hedge fund holdings that outperformed the market by 40 percentage points since May 2014 through May 30, 2019 (see the details here). We were also able to identify in advance a select group of hedge fund holdings that underperformed the market by 10 percentage points annually between 2006 and 2017. Interestingly the margin of underperformance of these stocks has been increasing in recent years. Investors who are long the market and short these stocks would have returned more than 27% annually between 2015 and 2017. We have been tracking and sharing the list of these stocks since February 2017 in our quarterly newsletter.

Alex Denner Sarissa Capital

Unlike some fund managers who are betting on Dow reaching 40000 in a year, our long-short investment strategy doesn’t rely on bull markets to deliver double digit returns. We only rely on hedge fund buy/sell signals. We’re going to take a look at the recent hedge fund action encompassing Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ).

How are hedge funds trading Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ)?

At the end of the second quarter, a total of 20 of the hedge funds tracked by Insider Monkey were bullish on this stock, a change of -26% from the previous quarter. By comparison, 27 hedge funds held shares or bullish call options in JAZZ a year ago. With hedgies’ capital changing hands, there exists an “upper tier” of noteworthy hedge fund managers who were boosting their stakes substantially (or already accumulated large positions).

JAZZ_oct2019

Among these funds, Renaissance Technologies held the most valuable stake in Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ), which was worth $364.4 million at the end of the second quarter. On the second spot was AQR Capital Management which amassed $147.5 million worth of shares. Moreover, Two Sigma Advisors, Arrowstreet Capital, and Sarissa Capital Management were also bullish on Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ), allocating a large percentage of their portfolios to this stock.

Since Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) has faced a decline in interest from the entirety of the hedge funds we track, it’s safe to say that there were a few hedge funds who were dropping their positions entirely in the second quarter. It’s worth mentioning that Andreas Halvorsen’s Viking Global sold off the largest stake of all the hedgies followed by Insider Monkey, worth an estimated $90.9 million in stock, and Michael Platt and William Reeves’s BlueCrest Capital Mgmt. was right behind this move, as the fund dumped about $14.6 million worth. These transactions are interesting, as total hedge fund interest dropped by 7 funds in the second quarter.

Let’s check out hedge fund activity in other stocks similar to Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ). These stocks are Teradyne, Inc. (NYSE:TER), Cypress Semiconductor Corporation (NASDAQ:CY), Caesars Entertainment Corp (NASDAQ:CZR), and Pearson PLC (NYSE:PSO). All of these stocks’ market caps match JAZZ’s market cap.

Ticker No of HFs with positions Total Value of HF Positions (x1000) Change in HF Position
TER 27 684058 3
CY 36 1306956 11
CZR 48 3654846 -9
PSO 4 7111 0
Average 28.75 1413243 1.25

View table here if you experience formatting issues.

As you can see these stocks had an average of 28.75 hedge funds with bullish positions and the average amount invested in these stocks was $1413 million. That figure was $745 million in JAZZ’s case. Caesars Entertainment Corp (NASDAQ:CZR) is the most popular stock in this table. On the other hand Pearson PLC (NYSE:PSO) is the least popular one with only 4 bullish hedge fund positions. Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) is not the least popular stock in this group but hedge fund interest is still below average. This is a slightly negative signal and we’d rather spend our time researching stocks that hedge funds are piling on. Our calculations showed that top 20 most popular stocks among hedge funds returned 24.4% in 2019 through September 30th and outperformed the S&P 500 ETF (SPY) by 4 percentage points. Unfortunately JAZZ wasn’t nearly as popular as these 20 stocks (hedge fund sentiment was quite bearish); JAZZ investors were disappointed as the stock returned -10.1% during the third quarter and underperformed the market. If you are interested in investing in large cap stocks with huge upside potential, you should check out the top 20 most popular stocks among hedge funds as many of these stocks already outperformed the market so far in 2019.

Disclosure: None. This article was originally published at Insider Monkey.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.